Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 1
2017 2
2018 2
2019 2
2021 2
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. Among authors: brackman d. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA. Pratz KW, et al. Among authors: brackman d. Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16. Am J Hematol. 2022. PMID: 36054316 Free article. No abstract available.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J. Brackman D, et al. Hematol Oncol. 2022 Apr;40(2):269-279. doi: 10.1002/hon.2964. Epub 2022 Feb 9. Hematol Oncol. 2022. PMID: 35043428 Free PMC article. Clinical Trial.
PharmGKB summary: very important pharmacogene information for ABCG2.
Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE. Fohner AE, et al. Among authors: brackman dj. Pharmacogenet Genomics. 2017 Nov;27(11):420-427. doi: 10.1097/FPC.0000000000000305. Pharmacogenet Genomics. 2017. PMID: 28858993 Free PMC article. Review. No abstract available.
Liposomal resiquimod for the treatment of Leishmania donovani infection.
Peine KJ, Gupta G, Brackman DJ, Papenfuss TL, Ainslie KM, Satoskar AR, Bachelder EM. Peine KJ, et al. Among authors: brackman dj. J Antimicrob Chemother. 2014 Jan;69(1):168-75. doi: 10.1093/jac/dkt320. Epub 2013 Aug 16. J Antimicrob Chemother. 2014. PMID: 23956375 Free PMC article.
15 results